Previous 10 | Next 10 |
ContraVir Pharmaceuticals (NASDAQ: CTRV ) +123% on encouraging CRV431 data . More news on: ContraVir Pharmaceuticals, Inc., Stitch Fix, Inc., Ciena Corporation, Stocks on the move, Read more ...
Gainers: SFIX +28.1% . IFRX +5.2% . REI +4.2% . FIVE +2.9% . SIEN +2.1% . More news on: Stitch Fix, Inc., InflaRx N.V., Ring Energy, Inc., Stocks on the move, , News on ETFs Read more ...
Gainers: ReWalk Robotics (NASDAQ: RWLK ) +126% . Genocea Biosciences (NASDAQ: GNCA ) +14% . Dean Foods (NYSE: DF ) +13% . RAVE Restaurant Group (NASDAQ: RAVE ) +11% . Medley Management (NYSE: MDLY ) +10% . Neon Therapeutics (NASDAQ: NTGN ) +10% . Allena Pharmaceuticals (NASDAQ:...
InflaRx N.V. (NASDAQ: IFRX ) -87% after IFX-1 flunks mid-stage study. More news on: InflaRx N.V., GameStop Corp., ChemoCentryx, Inc., Stocks on the move, Read more ...
Thinly traded InflaRx (NASDAQ: IFRX ) craters 82% premarket on robust volume in response to topline data from a Phase 2b clinical trial evaluating lead candidate IFX-1 in patients with a chronic inflammatory skin disorder called hidradenitis suppurativa (HS). More news on...
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1 treatment achieved a maximum HiSCR rate of 51.5 % at week 16, while placebo treatment resulted in a HiSC...
InflaRx (NASDAQ: IFRX ): Q1 GAAP EPS of -€0.38. More news on: InflaRx N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma Gangraenosum; first patient treated in AAV EU trial Corporate: U.S. operations expanded and new Non-Executive Directo...
JENA, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in pat...
Sector Technicals Last week, the XBI (SPDR Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) fell 4.16% and 3.38%, respectively. When markets have a tough week, take advantage of this opportunity to scan for stocks that are swimming upstream against the tide. Data by YCharts ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...